A discrete choice experiment on oral and injection treatment preferences among moderate‐to‐severe psoriasis patients in Japan

Abstract

AbstractLong‐term psoriasis (PsO) management remains challenging. With growing variation in treatment efficacy, cost, and modes of administration, patient preferences for different treatment characteristics are not well understood. A discrete choice experiment (DCE), informed by qualitative patient interviews, was conducted to assess patient preferences for different attributes of PsO treatments; 222 adult patients with moderate‐to‐severe PsO receiving systemic therapy participated in the DCE web survey. Better long‐term efficacy and lower cost were preferred (preference weights p < 0.05). Long‐term efficacy had the highest relative importance (RI) and mode of administration was as important as the outcome attributes (efficacy and safety). Patients also preferred oral to injectable administration. In subgroup analyses by disease severity, residence, psoriatic arthritis as a comorbidity, and gender, the trends for each subgroup were the same as the overall population although the extent of RI for administration mode varied. Mode of administration was more important for patients with moderate versus severe disease, or rural versus urban residence. This DCE utilized attributes related to both oral and injectable treatment as well as a broad study population of systemic treatment users. Preferences were further stratified by patient characteristics to explore trends in different subgroups. Understanding the RI of treatment attributes and the attribute trade‐offs acceptable to patients helps inform moderate‐to‐severe PsO systemic treatments decisions.